Director at Alnylam (NASDAQ: ALNY) receives RSUs and options

Rhea-AI Filing Summary

Alnylam Pharmaceuticals director Colleen F. Reitan received new equity awards as part of her compensation. She was granted 671 restricted stock units, each representing one share of common stock, increasing her direct holdings to 1,446 common shares after the award.

She also received a stock option covering 1,441 common shares at an exercise price of $298.48 per share. Both the RSUs and the option vest in full on the earlier of the first anniversary of the grant date or her earlier retirement or resignation, if that occurs no more than 90 days before the first anniversary.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Reitan Colleen F

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	1,441	$0.00	--
Grant/Award	Common Stock	671	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 1,441 shares (Direct, null); Common Stock — 1,446 shares (Direct, null)

Footnotes (1)

1. These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date. The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

Key Figures

RSU grant: 671 shares Shares owned after grant: 1,446 shares Stock option size: 1,441 shares +3 more

6 metrics

RSU grant 671 shares Restricted stock units granted to director on May 20, 2026

Shares owned after grant 1,446 shares Total common stock held directly after RSU award

Stock option size 1,441 shares Option covering common stock granted May 20, 2026

Option exercise price $298.48/share Conversion or exercise price for new stock option

Option expiration May 20, 2036 Expiration date of stock option grant

Vesting schedule 1-year cliff RSUs and option vest on first anniversary or qualifying retirement/resignation

Key Terms

restricted stock units (RSUs), Stock Option (Right to Buy), Second Amended and Restated 2018 Stock Incentive Plan, exercise price

4 terms

restricted stock units (RSUs) financial

"These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan."

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy) with underlying common stock shares."

Second Amended and Restated 2018 Stock Incentive Plan financial

"RSUs granted under the Second Amended and Restated 2018 Stock Incentive Plan."

exercise price financial

"conversion_or_exercise_price: 298.4800 for the stock option grant."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reitan Colleen F

(Last) (First) (Middle)

675 WEST KENDALL STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ALNYLAM PHARMACEUTICALS, INC. [ ALNY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/20/2026		A		671(1)	A	$0	1,446	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$298.48	05/20/2026		A		1,441		05/20/2027(2)	05/20/2036	Common Stock	1,441	$0	1,441	D

Explanation of Responses:

1. These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

2. The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

	Brett Budzinski, Attorney-in-Fact For: Colleen F. Reitan	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Colleen F. Reitan receive in this ALNY Form 4 filing?

Colleen F. Reitan received 671 restricted stock units and a stock option for 1,441 shares of Alnylam common stock. These equity awards were granted as compensation, not purchased in the open market.

How many ALNY shares does Colleen F. Reitan hold after this grant?

After the restricted stock unit grant, Colleen F. Reitan holds 1,446 shares of Alnylam common stock directly. This reflects her updated ownership following the award reported in the Form 4 filing.

What are the key terms of Colleen F. Reitan’s new ALNY stock option?

The new stock option covers 1,441 common shares with an exercise price of $298.48 per share. It is scheduled to vest in full on the earlier of the first anniversary of the grant date or qualifying retirement or resignation.

When do Colleen F. Reitan’s ALNY restricted stock units vest?

The 671 restricted stock units vest in full on the earlier of the first anniversary of the grant date or the date of her earlier retirement or resignation, provided that such retirement or resignation occurs no more than 90 days before that anniversary.

Are Colleen F. Reitan’s ALNY equity awards open-market purchases?

No. Both the 671 restricted stock units and the 1,441-share stock option are compensation grants. The Form 4 describes them as awards, not open-market buy or sell transactions involving Alnylam stock.